JP2022512686A - レチンアルデヒドデヒドロゲナーゼをコードする修飾ｒｎａの使用 - Google Patents

レチンアルデヒドデヒドロゲナーゼをコードする修飾ｒｎａの使用 Download PDF

Info

Publication number
JP2022512686A
JP2022512686A JP2021520209A JP2021520209A JP2022512686A JP 2022512686 A JP2022512686 A JP 2022512686A JP 2021520209 A JP2021520209 A JP 2021520209A JP 2021520209 A JP2021520209 A JP 2021520209A JP 2022512686 A JP2022512686 A JP 2022512686A
Authority
JP
Japan
Prior art keywords
virus
vaccine
vaccine according
protein
raldh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021520209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512686A5 (https=
Inventor
エイドリアン，ウルリッヒ，エイチ． フォン
ラポソ，ブルーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2022512686A publication Critical patent/JP2022512686A/ja
Publication of JP2022512686A5 publication Critical patent/JP2022512686A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01036—Retinal dehydrogenase (1.2.1.36)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
JP2021520209A 2018-10-10 2019-10-10 レチンアルデヒドデヒドロゲナーゼをコードする修飾ｒｎａの使用 Pending JP2022512686A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743943P 2018-10-10 2018-10-10
US62/743,943 2018-10-10
PCT/US2019/055543 WO2020077045A1 (en) 2018-10-10 2019-10-10 Uses of modified rna encoding retinaldehyde dehydrogenase

Publications (2)

Publication Number Publication Date
JP2022512686A true JP2022512686A (ja) 2022-02-07
JP2022512686A5 JP2022512686A5 (https=) 2022-10-11

Family

ID=70164700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520209A Pending JP2022512686A (ja) 2018-10-10 2019-10-10 レチンアルデヒドデヒドロゲナーゼをコードする修飾ｒｎａの使用

Country Status (6)

Country Link
US (2) US20210338709A1 (https=)
EP (1) EP3863646A4 (https=)
JP (1) JP2022512686A (https=)
AU (1) AU2019356940A1 (https=)
CA (1) CA3115522A1 (https=)
WO (1) WO2020077045A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240124532A1 (en) * 2021-01-29 2024-04-18 Institut National De La Santé Et De La Recherche Médicale (Inserm) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263340A1 (en) * 2005-04-29 2006-11-23 Andrian Ulrich H V Treating gastrointestinal diseases with modulators of retinoic acid
WO2013036914A1 (en) * 2011-09-08 2013-03-14 University Of Florida Research Foundation, Inc. Materials and methods for modulating immune responses
US20160051669A1 (en) * 2014-08-21 2016-02-25 Georgia Regents University Research Institute, Inc. Compositions and methods for selectively modulating tregs
US10238741B2 (en) * 2014-10-10 2019-03-26 The Trustees Of Columbia University In The City Of New York Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
EP4523756A3 (en) * 2015-02-13 2025-05-28 Transgene Immunotherapeutic vaccine and antibody combination therapy
EP3308800B1 (en) * 2015-06-10 2021-08-25 The University of Tokyo Adjuvant for vaccines, vaccine, and immunity induction method
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOLECHEK, SUSAN A. ET AL.: ""Retinaldehyde dehydrogenase 2 as a molecular adjuvant forenhancement of mucosal immunity during DN", VACCINE, vol. 34, no. 46, JPN6023033918, November 2016 (2016-11-01), pages 5629 - 5635, XP029772632, ISSN: 0005233570, DOI: 10.1016/j.vaccine.2016.09.013 *
KARIKO, KATALIN ET AL.: ""Suppression of RNA Recognition by Toll-like Receptors: The Impact ofNucleoside Modification and th", IMMUNITY, vol. 23, no. 2, JPN6023033920, August 2005 (2005-08-01), pages 165 - 175, ISSN: 0005131307 *
SAHIN, UGUR ET AL.: ""mRNA-based therapeutics - developing a new class of drugs"", NATURE REVIEWS DRUG DISCOVERY, vol. 13, no. 10, JPN6023033919, 19 September 2014 (2014-09-19), pages 759 - 780, XP037134862, ISSN: 0005233571, DOI: 10.1038/nrd4278 *

Also Published As

Publication number Publication date
US20210338709A1 (en) 2021-11-04
US20250339458A1 (en) 2025-11-06
CA3115522A1 (en) 2020-04-16
AU2019356940A1 (en) 2021-05-13
WO2020077045A1 (en) 2020-04-16
EP3863646A1 (en) 2021-08-18
EP3863646A4 (en) 2022-09-28

Similar Documents

Publication Publication Date Title
JP7625568B2 (ja) 癌ワクチン
JP6949845B2 (ja) Ｒｎａ分子組成物の作製方法
JP2023164537A (ja) Ｒｎａ癌ワクチン
JP7145579B2 (ja) 核酸カーゴ用のハイブリッド担体
WO2018232355A1 (en) Rna antibodies
KR20250061730A (ko) 스테롤 기반 이온화 가능한 지질 및 이를 포함하는 지질 나노입자
CN1194002C (zh) 短链化多核苷酸及其制备方法
JP2025503994A (ja) コロナウイルスワクチン
US20230381233A1 (en) Compositions and methods for t cell engineering
US20250339458A1 (en) Uses of modified rna encoding retinaldehyde dehydrogenase
CN115777017A (zh) 用于t细胞工程改造的组合物及方法
JP2023175686A (ja) ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
US11633473B2 (en) Stimulator of Interferon Genes (STING) ligands and uses thereof
US20230113157A1 (en) Compositions and methods for t cell engineering
WO2021237055A1 (en) Functional lipid derivatives and uses thereof
WO2024081858A1 (en) Kras/tp53 neoantigen specific t cell receptors
US20250041278A1 (en) Tlr8 agonist for modulating immune response
US20250000971A1 (en) Tlr4 agonist for modulating immune response
WO2025063844A1 (en) Enhancement of t cell mediated therapies with a dna hypomethylating agent and a sumoylation inhibitor
Rapp mRNA vaccines A bridge between preventive and therapeutic medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240110